Patents by Inventor Benoit Favier

Benoit Favier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-LILRB ANTIBODIES AND USES THEREOF
    Publication number: 20230382991
    Abstract: An antagonist antibody, or an antigen binding fragment thereof, binds both to human and macaque LILRB1 and/or LILRB2, and has diagnostic and therapeutic uses.
    Type: Application
    Filed: October 12, 2021
    Publication date: November 30, 2023
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Benoit FAVIER, Sixtine COINDRE, Anne WIJKHUISEN, Stéphanie SIMON, Roger LE GRAND, Olivier LAMBOTTE
  • HLA-G POLYPEPTIDES AND PHARMACEUTICAL USES THEREOF
    Publication number: 20110274711
    Abstract: The present invention relates to novel proteins and pharmaceutical uses thereof The invention more specifically relates to novel proteins comprising the sequence of an HLA-5 antigen fused to the sequence of a b2 microglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection.
    Type: Application
    Filed: November 4, 2009
    Publication date: November 10, 2011
    Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, HLA-G TECHNOLOGIES
    Inventors: Benoit Favier, Edgardo D. Carosella, Joël Lemaoult
  • HLA-G PROTEINS AND PHARMACEUTICAL USES THEREOF
    Publication number: 20110268737
    Abstract: The present invention relates to novel proteins and pharmaceutical uses thereof. The invention more specifically relates to novel fusion proteins comprising a domain of an HLA-G antigen fused to an Fc domain of an immunoglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection.
    Type: Application
    Filed: November 4, 2009
    Publication date: November 3, 2011
    Applicants: COMMISSARIAT A L'ENEGRIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, HLA-G TECHNOLOGIES
    Inventors: Benoit Favier, Edgardo D. Carosella, Joël Lemaoult